Immunosuppressive therapy in lupus nephritis - The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

Houssiau, FA; Vasconcelos, C; D'Cruz, D; Sebastiani, GD; Garrido, ED; Danieli, MG; Abramovicz, D; Blockmans, D; Mathieu, A; DİRESKENELİ, RAFİ; Galeazzi, M; Gul, A; Levy, Y; Petera, P; Popovic, R; Petrovic, R; Sinico, RA; Cattaneo, R; Font, J; Depresseux, G; Cosyns, JP; Cervera, R

doi:10.1002/art.10461

Immunosuppressive therapy in lupus nephritis - The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

Atıf İçin Kopyala

Houssiau F., Vasconcelos C., D'Cruz D., Sebastiani G., Garrido E., Danieli M., ...Daha Fazla

ARTHRITIS AND RHEUMATISM, cilt.46, sa.8, ss.2121-2131, 2002 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 46 Sayı: 8
Basım Tarihi: 2002
Doi Numarası: 10.1002/art.10461
Dergi Adı: ARTHRITIS AND RHEUMATISM
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2121-2131
Marmara Üniversitesi Adresli: Evet

Özet

Objective. Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that is usually treated with an extended course of intravenous (IV) cyclophosphamide (CYC). Given the side effects of this regimen, we evaluated the efficacy and the toxicity of a course of low-dose IV CYC prescribed as a remission-inducing treatment, followed by azathioprine (AZA) as a remission-maintaining treatment.